Updated Guidelines and the Current CSU Treatment Landscape

Segment summary: This episode titled “Updated Guidelines and the Current CSU Treatment Landscape,” reviews the recently updated international CSU treatment guideline and how it has changed clinical practice. While one-size-fits-all dermatology guidelines are viewed with some skepticism, this update is considered practical because it elevates all three advanced therapy classes to parity rather than ranking them sequentially. The stepwise approach is outlined: minimal workup, a thorough history, and first-line treatment with a second-generation H1 antihistamine dosed up to four times the standard amount, with a caution to avoid combination antihistamine-decongestant formulations at high doses due to hypertension risk.

When antihistamine monotherapy fails, roughly half of patients by the panelist’s estimate, the guideline now recommends moving to one of three advanced therapy classes: an injectable anti-IgE biologic, an injectable biologic targeting the IL-4 receptor pathway, or an oral BTK inhibitor, with cyclosporine reserved as a later option for refractory cases. Rather than a fixed hierarchy, choosing among the three advanced options is described through structured shared decision-making, presenting patients with no more than two choices at a time, starting with questions about comorbid asthma or other atopic conditions, since certain biologics carry additional approvals for those indications.

For patients without such comorbidities, the choice is framed around route of administration and speed of relief: a fast-acting oral pill taken twice daily versus an injectable that works somewhat more slowly but requires dosing only monthly or every two weeks. By the time most CSU patients reach a specialist after a diagnostic delay of two or more years, they have typically exhausted first-line therapy, making this discussion of advanced options especially timely. In the next episode, “Mechanisms of Action Behind Advanced CSU Therapies,” the panel breaks down the autoimmune pathways driving CSU and explains exactly how each of the three advanced therapy classes interrupts the disease process.